Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance and continuous therapy for multiple myeloma.
Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P. Richardson PG, et al. Among authors: facon t. Expert Rev Anticancer Ther. 2018 Aug;18(8):751-764. doi: 10.1080/14737140.2018.1490181. Epub 2018 Jul 3. Expert Rev Anticancer Ther. 2018. PMID: 29932776 Review.
Double-intensive therapy in high-risk multiple myeloma.
Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Casassus P, Guilhot F, Ifrah N, Gandhour C. Harousseau JL, et al. Among authors: facon t. Blood. 1992 Jun 1;79(11):2827-33. Blood. 1992. PMID: 1350228 Free article.
[Standard treatment of multiple myeloma].
Facon T. Facon T. Rev Med Interne. 1999 Jul;20(7):611-21. doi: 10.1016/s0248-8663(99)80112-x. Rev Med Interne. 1999. PMID: 10434353 Review. French.
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, Schroyens W, Hulin C, Schots R, Marin P, Guilhot F, Granena A, De Waele M, Pigneux A, Méresse V, Clark P, Reiffers J. Facon T, et al. Blood. 1999 Aug 15;94(4):1218-25. Blood. 1999. PMID: 10438709 Free article. Clinical Trial.
Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C, Grosbois B, Beris P, Duguet C, Attal M, Harousseau JL, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Among authors: facon t. Hematol J. 2000;1(3):186-9. doi: 10.1038/sj.thj.6200031. Hematol J. 2000. PMID: 11920188 Clinical Trial.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. Among authors: facon t. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.
415 results